Recruiting

INCA036873 for Advanced Solid Tumors and Hematological Malignancies

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

INCA036873

Drug
Who is being recruted

Urogenital Diseases+27

+ Adenocarcinoma

+ Carcinoma

Over 18 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
Study Start: January 2026
See protocol details

Summary

Principal SponsorIncyte Corporation
Study ContactIncyte Corporation Call Center (US)More contacts
Last updated: February 11, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 8, 2026

Actual date on which the first participant was enrolled.

This clinical trial is focused on testing a new drug called INCA036873 to see if it is safe and can be tolerated by people who have advanced solid tumors or blood-related cancers. These conditions are often serious and hard to treat, so finding new treatment options is important. By studying this drug, researchers hope to uncover a new potential way to help these patients, which could lead to better outcomes and improved quality of life. Participants in the study will receive the INCA036873 drug, and researchers will closely monitor how they respond to it. The drug is given to see if it causes any side effects and to understand how it acts in the body. Although the study does not list specific measurements, it typically involves regular health check-ups and tests to observe any changes in the participants' condition. There is a focus on ensuring the safety of the participants while gathering important information about the drug's effects.

Official TitleA Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916
Principal SponsorIncyte Corporation
Study ContactIncyte Corporation Call Center (US)More contacts
Last updated: February 11, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

280 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesAdenocarcinomaCarcinomaCarcinoma, Renal CellFemale Urogenital Diseases and Pregnancy ComplicationsHematologic DiseasesHemic and Lymphatic DiseasesImmune System DiseasesImmunoproliferative DisordersKidney DiseasesKidney NeoplasmsLymphatic DiseasesLymphomaLymphoma, Non-HodgkinLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Glandular and EpithelialUrogenital NeoplasmsUrologic DiseasesUrologic NeoplasmsLymphoma, B-CellLymphoma, T-CellLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralHematologic NeoplasmsFemale Urogenital DiseasesMale Urogenital Diseases

Criteria

6 inclusion criteria required to participate
Age ≥18 years.
ECOG performance status of 0 or 1.
Tumor tissue available for central testing.
Disease progression, relapse, or refractory to prior therapy: ccRCC: ≥1 prior line incl. ICI + TKI, DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage, PTCL/CTCL: ≥1 prior systemic therapy.
Show More Criteria
8 exclusion criteria prevent from participating
Untreated or progressive CNS disease unless previously treated and stable.
Other active invasive malignancy within 2 years (except certain low-risk cancers).
Prior CD70-targeting therapy, including CAR T.
ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
INCA036873 will be administered at the protocol defined dose.

Group II

Experimental
INCA036873 will be administered at the protocol defined dose.

Group III

Experimental
INCA036873 will be administered at the protocol defined dose.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 22 locations

Recruiting

Scri Oncology Partners

Nashville, United StatesOpen Scri Oncology Partners in Google Maps
Recruiting

Macquarie University Hospital

Sydney, Australia
Recruiting

Peter Maccallum Cancer Centre-Royal Melbourne Hospital

Melbourne, Australia
Recruiting soon

City of Hope Medical Center

Duarte, United States
Recruiting
22 Study Centers